MICRO-X LIMITED (MX1)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MX1

MX1 - MICRO-X LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.43
Index:

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.027

11 Aug
2026

-0.001

OPEN

$0.03

-3.57%

HIGH

$0.03

270,975

LOW

$0.03

TARGET
$0.08 196.3% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
MX1: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 2.3 - 2.1 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-2.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx13.1 M
Book Value Per Share xxxxxxxxxxxxxxx1.1
Net Operating Cash Flow xxxxxxxxxxxxxxx-8.6 M
Net Profit Margin xxxxxxxxxxxxxxx-106.45 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-128.19 %
Return on Invested Capital xxxxxxxxxxxxxxx-100.67 %
Return on Assets xxxxxxxxxxxxxxx-56.71 %
Return on Equity xxxxxxxxxxxxxxx-128.19 %
Return on Total Capital xxxxxxxxxxxxxxx-104.25 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-8.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx4 M
Long Term Debt xxxxxxxxxxxxxxx3 M
Total Debt xxxxxxxxxxxxxxx7 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx3 M
Price To Book Value xxxxxxxxxxxxxxx4.37

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx0.77 %
Cost of Goods Sold xxxxxxxxxxxxxxx22 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx8 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

04/08/2026

1

Speculative Buy

$0.08

196.30%

Micro-X announced its June quarter update which showed management continued to focus on moving its funding development programs forward and achieving several major technical milestones, Morgans highlights.

Head CT started its first human imaging pilot study and received $1.5m in milestone payments. The full body CT moved to manufacture a prototype and received a $1.6m milestone payment.

Airport security checkpoint received a $1.3m extension to speed up the AI and threat detection software development from the US Department of Homeland Security.

The analyst notes customer receipts were much lower than anticipated at $0.2m. Revenue forecasts for FY26 are lowered by -15.6% due to the 4Q sales update. The net loss is now forecast to rise to -$10.3m from -$6.9m.

Speculative Buy retained with a lower target price of 8c, down from 15c.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -2.10 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.90 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

MX1 STOCK CHART

FNArena News on MX1

1
FNArena Corporate Results Monitor – 23-02-2026

Feb 23 2026 - Australia
2
Rudi’s View: February Favourites & Avoids

Jan 29 2026 - Rudi's View
3
Rudi’s View: A Glass Half-Full Outlook

Sep 03 2025 - Rudi's View
4
FNArena Corporate Results Monitor – 29-08-2025

Aug 29 2025 - Australia
5
FNArena Corporate Results Monitor – 29-02-2024

Feb 29 2024 - Australia

Latest Medical Equipment & Devices News

1
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
2
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
3
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
4
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
5
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
6
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
7
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
8
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
9
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
10
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest